Chris Benecchi appointed COO by Inventiva

Inventiva, a biopharmaceutical company, announces the appointment of Chris Benecchi as Chief Operating Officer. His extensive experience in the biopharmaceutical industry will be leveraged to lead the company's operational readiness ahead of the expected results of the Phase 3 NATiV3 study of lanifibranor. Results are expected in the fourth quarter of 2026.

Benecchi has 30 years of experience, having held various leadership roles, notably at Sage Therapeutics and UCB. At Inventiva, his mission will be to build the organization necessary for a potential launch of lanifibranor, targeting the MASH market in the United States, as early as 2028.